These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 6085926

  • 1. Prevalence of AIDS-associated retrovirus and antibodies among male homosexuals at risk for AIDS in Greenwich Village.
    Casareale D, Dewhurst S, Sonnabend J, Sinangil F, Purtilo DT, Volsky DJ.
    AIDS Res; ; 1(6):407-21. PubMed ID: 6085926
    [Abstract] [Full Text] [Related]

  • 2. [Antibodies against human T-cell leukemia virus type III in acquired immunodeficiency syndrome and persistent lymphadenopathy].
    Wernicke D, v d Helm K, Abb J, Eberle J, Zoulek G, Pleyl G, Deinhardt F, Riethmüller G, Ziegler-Heitbrock HW, Rieber EP.
    Dtsch Med Wochenschr; 1984 Nov 09; 109(45):1709-11. PubMed ID: 6094134
    [Abstract] [Full Text] [Related]

  • 3. IgM and IgG antibodies to human T cell lymphotropic retrovirus (HTLV-III) in lymphadenopathy syndrome and subjects at risk for AIDS in Italy.
    Aiuti F, Rossi P, Sirianni MC, Carbonari M, Popovic M, Sarngadharan MG, Contu L, Moroni M, Romagnani S, Gallo RC.
    Br Med J (Clin Res Ed); 1985 Jul 20; 291(6489):165-6. PubMed ID: 2990634
    [Abstract] [Full Text] [Related]

  • 4. Antibodies to acquired immune deficiency syndrome (AIDS)-associated virus (HTLV-III/LAV) in Venezuelan populations.
    Volsky DJ, Rodriguez L, Dewhurst S, Sinangil F, Sakai K, Merino F, Esparza B, De Salvo L.
    AIDS Res; 1986 Jul 20; 2(2):79-92. PubMed ID: 3013223
    [Abstract] [Full Text] [Related]

  • 5. Testing for antibodies to AIDS-associated retrovirus (HTLV-III/LAV) by indirect fixed cell immunofluorescence: specificity, sensitivity, and applications.
    Hedenskog M, Dewhurst S, Ludvigsen C, Sinangil F, Rodriguez L, Wu YT, Volsky DJ.
    J Med Virol; 1986 Aug 20; 19(4):325-34. PubMed ID: 3018138
    [Abstract] [Full Text] [Related]

  • 6. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations.
    Ragni MV, Lewis JH, Bracken M, Toth R, Stokes J, Steffensen DO.
    Transfusion; 1986 Aug 20; 26(3):299-301. PubMed ID: 3010516
    [Abstract] [Full Text] [Related]

  • 7. HTLV-III/LAV antibodies and virus in hemophilia patients in Nebraska: survey and initiation of a prospective study.
    Volsky DJ, Wu YT, Sinangil F, Goldsmith JC.
    AIDS Res; 1986 Feb 20; 2(1):51-61. PubMed ID: 2424467
    [Abstract] [Full Text] [Related]

  • 8. Survey of the prevalence of AIDS-associated virus (LAV) infection in Japan.
    Tsuchie H, Kurimura T, Hinuma Y.
    J Infect; 1985 May 20; 10(3):272-6. PubMed ID: 2993425
    [Abstract] [Full Text] [Related]

  • 9. Immune impairments and antibodies to HTLVIII/LAV in asymptomatic male homosexuals in Israel: relevance to the risk of acquired immune deficiency syndrome (AIDS).
    Bentwich Z, Saxinger C, Ben-Ishay Z, Burstein R, Berner Y, Pecht M, Trainin N, Levin S, Handzel ZT.
    J Clin Immunol; 1987 Sep 20; 7(5):376-80. PubMed ID: 2443528
    [Abstract] [Full Text] [Related]

  • 10. Determination of antibodies against LAV/HTLV III: comparative evaluation of four different commercial test kits.
    Abb J.
    AIDS Res; 1986 Sep 20; 2(2):93-7. PubMed ID: 3013224
    [Abstract] [Full Text] [Related]

  • 11. Persistent infection with human T-lymphotropic virus type III/lymphadenopathy-associated virus in apparently healthy homosexual men.
    Jaffe HW, Feorino PM, Darrow WW, O'Malley PM, Getchell JP, Warfield DT, Jones BM, Echenberg DF, Francis DP, Curran JW.
    Ann Intern Med; 1985 May 20; 102(5):627-8. PubMed ID: 2984973
    [Abstract] [Full Text] [Related]

  • 12. Establishment of retrovirus-, Epstein-Barr virus-positive B-lymphoblastoid cell lines derived from individuals at risk for acquired immune deficiency syndrome (AIDS).
    Casareale D, Sinangil F, Hedeskog M, Ward W, Volsky DJ, Sonnabend J.
    AIDS Res; 1985 May 20; 1(4):253-70. PubMed ID: 6085940
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serological differences between human T-lymphotropic virus type-I (HTLV-I) and HTLV-III/LAV.
    Harada S, Purtilo DT, Koyanagi Y, Yamamoto N.
    Microbiol Immunol; 1986 May 20; 30(6):533-44. PubMed ID: 3018457
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High prevalence and high titers of LAV/HTLV-III antibodies in healthy hemophiliacs in the midwestern United States.
    Goldsmith JC, Dewhurst S, Hedenskog M, Casareale D, Volsky DJ.
    Am J Med; 1986 Oct 20; 81(4):579-83. PubMed ID: 3532787
    [Abstract] [Full Text] [Related]

  • 17. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
    Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS.
    J Immunol; 1987 Feb 15; 138(4):1064-7. PubMed ID: 3027168
    [Abstract] [Full Text] [Related]

  • 18. Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood.
    Esteban JI, Shih JW, Tai CC, Bodner AJ, Kay JW, Alter HJ.
    Lancet; 1985 Nov 16; 2(8464):1083-6. PubMed ID: 2865566
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.